Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Alloy vs Genesis Health

By GLP-1 ScorecardUpdated

AlloyFactor scores not reassessed.
Site position #91

Higher score

Genesis HealthFactor scores not reassessed.
Site position #318

Lower score

Score comparison

Alloy has the higher recorded score — 72.2/100 to 61.4/100.

Alloy grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Alloy combines a $99 monthly Weight Care fee with separately priced branded and compounded medication. Confirm the dose price, state availability and both cancellation deadlines.

Before you choose

Before comparing the headline prices, the Alloy review and the Genesis Health review set out the plan length, renewal date and extra fees behind each semaglutide figure in the table below, and the semaglutide cost page compares published rates across the field. A lower starting price can still mean a larger bill once a longer commitment or a separate membership is added.

If neither one fits, Alloy vs GOAL.MD and CoreAge Rx vs Genesis Health compare each of them with another graded program, and the list of alternatives to Alloy ranks the programs closest to Alloy on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.

Of the sellers that pay us a commission, the MyDrHank review covers one graded close to these two, at 68.2/100. That relationship never changes a grade, and the review lists what we could not verify.

We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.

Factor by factor

These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.

Cost valueAlloy +18
70
52
Dose & formulationAlloy +16
93
77
Clinical oversightAlloy +24
79
55
Labs & monitoringGenesis Health +9
54
63
FulfillmentGenesis Health +8
65
73
Contract termsAlloy +8
55
47
Alloy · top barGenesis Health · bottom bar

The numbers

Swipe or scroll to compare both providers.

MetricAlloyGenesis Health
WeighScore72.2/10061.4/100
GradeCC
Site position#91#318
SemaglutideFrom $169/mo (compounded, including care)$175/mo (compounded; published monthly plan)
TirzepatideFrom $199/mo (compounded, including care)$225/mo (compounded; published monthly plan)
CoverageCompounded options exclude AL, AR, CA, NV, LA, MS and DCCoverage not published
Brand-name accessYesYes
Oral / sublingualYesYes
Alloy

Site position #91 · C

Factor scores not reassessed.

Strengths

  • Publishes the recurring care fee separately from medication
  • Lists branded and compounded options and includes ongoing physician messaging

What to consider

  • Medication prices are advertised starts, with care billed separately
  • Care renewal and shipment cancellation have different deadlines
  • Compounded options are unavailable in seven listed jurisdictions
Genesis Health

Site position #318 · C

Factor scores not reassessed.

FDAWarning letter issued to Genesis Health International Inc. dba Genesis in February 2026. See the FDA warning-letter database.

Strengths

  • Lists monthly and longer-term prices separately

What to consider

  • The refund policy requires 15 days’ notice before the next billing date
  • FDA issued a warning letter about prior promotional claims in February 2026

Featured provider

CoreAge Rx

CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.

Commercial relationships affect this placement. The score comparison above is separate.

Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.

← Back to the scorecard